Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00238082 · ClinicalTrials.gov registry record · NA

The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

A NA study, sponsored by National Jewish Health.

Terminated
Registry status
NA
Development phase
20
Enrollment target

NCT00238082 is a NA study that was terminated before completion, run by National Jewish Health. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00238082, a NA study, was terminated before completion, sponsored by National Jewish Health.

TERMINATED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.

Interventions

  • DRUG HFA-134A Beclomethasone DIpropionate (QVAR)

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 1999-11
Est. Completion 2005-02
Phase NA

Sponsor

National Jewish Health

83 total trials

What the Registry Record Tells You About NCT00238082

The ClinicalTrials.gov registry entry for NCT00238082 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which HFA-134A Beclomethasone DIpropionate (QVAR) is the first listed.

NCT00238082 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00238082 about?

NCT00238082 is a clinical study titled "The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease". This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7...

What is the current status of trial NCT00238082?

This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 1999-11. Estimated completion is 2005-02.

What interventions are being tested in trial NCT00238082?

The interventions under investigation include: HFA-134A Beclomethasone DIpropionate (QVAR) (DRUG).

Who is sponsoring clinical trial NCT00238082?

This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.